PharmGen Science, Inc.(KR:004720)
₩3,025.00+55.00 (+1.85%)
KR:004720
PharmGen Science, Inc. financials statements
₩3,025.00
At close:+55.00 (+1.85%)
Want to see KR:004720 full AI Analyst Report?
PharmGen Science, Inc. (004720) Income Statement
PharmGen Science, Inc. Income Statement
Last quarter (Q2 2026), PharmGen Science, Inc.'s total revenue was ₩47.72B, an increase of 4.02% from the same quarter last year. In Q2, PharmGen Science, Inc.'s net income was ₩-13.58B. See PharmGen Science, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ₩ 173.07B | ₩ 171.29B | ₩ 166.78B | ₩ 150.93B | ₩ 109.87B | |
| ₩ 109.13B | ₩ 108.03B | ₩ 96.20B | ₩ 81.30B | ₩ 60.80B | |
| ₩ 103.15B | ₩ 97.39B | ₩ 87.07B | ₩ 73.82B | ₩ 64.10B | |
| Depreciation and Amortization | ₩ 4.56B | ₩ 4.64B | ₩ 4.25B | ₩ 3.37B | ₩ 3.14B |
| ₩ 10.53B | ₩ 10.79B | ₩ 13.37B | ₩ 10.78B | ₩ -254.11M | |
| ₩ 5.99B | ₩ 10.64B | ₩ 9.13B | ₩ 9.32B | ₩ -4.94B | |
| ₩ -157.09B | ₩ -9.63B | ₩ -1.14B | ₩ 82.49B | ₩ 46.99B | |
| ₩ -151.10B | ₩ 1.02B | ₩ 7.99B | ₩ 89.96B | ₩ 41.95B | |
| ₩ -116.64B | ₩ 2.79B | ₩ 5.73B | ₩ 70.06B | ₩ 32.47B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ -5312.85 | ₩ 154.07 | ₩ 374.00 | ₩ 4498.10 | ₩ 2206.02 |
| Diluted EPS | ₩ -5312.85 | ₩ 152.25 | ₩ 324.00 | ₩ 3369.29 | ₩ 1814.33 |
| Weighted Average Shares Outstanding | 21.95M | 18.14M | 16.28M | 15.57M | 14.72M |
| Weighted Average Shares Outstanding (Diluted) | 21.95M | 21.78M | 20.80M | 21.59M | 18.60M |
Currency in KRW
